These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32631828)

  • 1. Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis.
    Al-Shaer MH; Märtson AG; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Houpt ER; Ashkin D; Griffith DE; Cegielski JP; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug-resistant tuberculosis.
    Mugabo P; Mulubwa M
    Br J Clin Pharmacol; 2021 Oct; 87(10):3863-3870. PubMed ID: 33620754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients.
    Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0027821. PubMed ID: 34310215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
    Alghamdi WA; Alsultan A; Al-Shaer MH; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Schmidt S; Heysell SK; Kempker RR; Cegielski JP; Peloquin CA
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Mpagama SG; Srivastava S; Bendet P; Koeuth T; Lee PS; Heysell SK; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S317-S326. PubMed ID: 30496457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Linezolid in Tuberculosis Patients: Dosing Regimen Simulation and Target Attainment Analysis.
    Alghamdi WA; Al-Shaer MH; An G; Alsultan A; Kipiani M; Barbakadze K; Mikiashvili L; Ashkin D; Griffith DE; Cegielski JP; Kempker RR; Peloquin CA
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32778547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug-resistant tuberculosis therapy.
    Boonpeng A; Jaruratanasirikul S; Wattanavijitkul T; Nawakitrangsan M; Samaeng M
    Biopharm Drug Dispos; 2021 Jul; 42(7):329-337. PubMed ID: 34117648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.
    Alsaad N; Dijkstra JA; Akkerman OW; de Lange WC; van Soolingen D; Kosterink JG; van der Werf TS; Alffenaar JW
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3942-7. PubMed ID: 27067336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
    Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
    Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
    Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.
    Yun HY; Chang MJ; Jung H; Chang V; Wang Q; Strydom N; Yoon YR; Savic RM
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0189321. PubMed ID: 35938799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of ethionamide in patients with tuberculosis.
    Zhu M; Namdar R; Stambaugh JJ; Starke JR; Bulpitt AE; Berning SE; Peloquin CA
    Tuberculosis (Edinb); 2002; 82(2-3):91-6. PubMed ID: 12356460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Modeling, Simulation, and Development of a Limited Sampling Strategy of Cycloserine in Patients with Multidrug-/Extensively Drug-Resistant Tuberculosis.
    van der Galiën R; Boveneind-Vrubleuskaya NV; Peloquin C; Skrahina A; Touw DJ; Alffenaar JC
    Clin Pharmacokinet; 2020 Jul; 59(7):899-910. PubMed ID: 31981103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid Pharmacokinetics/Pharmacodynamics-Based Optimal Dosing for Multidrug-Resistant Tuberculosis.
    Zhou W; Nie W; Wang Q; Shi W; Yang Y; Li Q; Zhu H; Liu Z; Ding Y; Lu Y; Chu N
    Int J Antimicrob Agents; 2022 Jun; 59(6):106589. PubMed ID: 35405268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.
    Chirehwa MT; Court R; de Kock M; Wiesner L; de Vries N; Harding J; Gumbo T; Maartens G; Warren R; Denti P; McIlleron H
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
    van Rijn SP; Zuur MA; van Altena R; Akkerman OW; Proost JH; de Lange WC; Kerstjens HA; Touw DJ; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
    Zhu Y; Zhu L; Davies Forsman L; Paues J; Werngren J; Niward K; Schön T; Bruchfeld J; Xiong H; Alffenaar JW; Hu Y
    Antimicrob Agents Chemother; 2023 May; 67(5):e0170022. PubMed ID: 37097151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
    de Kock L; Sy SK; Rosenkranz B; Diacon AH; Prescott K; Hernandez KR; Yu M; Derendorf H; Donald PR
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6242-50. PubMed ID: 25114132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.
    Alsultan A; An G; Peloquin CA
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3800-7. PubMed ID: 25870068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.